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Antimicrobial activityAbstract A variety of novel 2-methylquinazolin-4(3H)-one derivatives (1–29) bearing urea, thio-
urea and sulphonamide functionalities at position 3 of biological interest have been synthesized
and screened for their anti-inﬂammatory (TNF-a and IL-6) and antimicrobial activities (antibacte-
rial and antifungal). ‘‘Biological evaluation study revealed that the compounds 3, 4, 6, 9, 16 and 18
were found to have promising anti-inﬂammatory activity (up to 62–84% TNF-a and 73–92% IL-6
inhibitory activity) at concentration of 10 lM with reference to standard dexamethasone (75%
TNF-a and 84% IL-6 inhibitory activities at 1 lM) and 7, 10, 12, 23, 25 and 28 have antimicrobial
activity at MIC of 10–30 lg/mL against selected pathogenic bacteria and fungi.’’
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The current interest in the development of new antimicrobial
agents can be partially ascribed both to the increasing emer-
gence of bacterial resistance to antibiotic therapy and to newly
emerging pathogens (Cohen, 2000; Barrett and Barrett, 2003).Despite a number of antibiotics available for the treatment of
bacterial infections, emergence of multi-drug resistant organ-
isms has posed a great challenge to the scientists and it is well
known that non-steroidal anti-inﬂammatory drugs (NSAIDs)
are associated with several side effects such as gastrointestinal
mucosal damage, bleeding, intolerance and renal toxicity
(Bombardier et al., 2000; Silverstien et al., 2000).
Non-steroidal anti-inﬂammatory drugs (NSAIDs) are ther-
apeutically important in the treatment of rheumatoid arthritis
and in various types of inﬂammatory conditions, but their ther-
apeutic utility has been limited due to their frequently observed
gastrointestinal side effects. Thus, there is an urgent need for
new targets that are required for the design and development
of novel anti-inﬂammatory agents as an alternative to NSAIDs
(Shishoo et al., 1999). Tumour necrosis factor alpha (TNF-a)n-4(3H)-
25
2 A.P. Keche, V.M. Kambleand interleukin-6 (IL-6) are the two important multifunctional
pro-inﬂammatory cytokines involved in the pathogenesis of
autoimmune, inﬂammatory, cardiovascular, neurodegenerative
and cancer diseases through a series of cytokine signalling path-
ways (Papadakis and Targan, 2000; Krishnamoorthy and
Honn, 2006). IL-6 contributes to the initiation and extension
of the inﬂammatory process and considered as a central medi-
ator in a range of inﬂammatory diseases but it has not received
the desired attention in drug discovery (Dominic and Raj,
2009). TNF-a and IL-6 are thus pharmaceutically important
molecular targets for the treatment of the above-mentioned dis-
eases. So there appears to be a need for the development of new,
safer and more active NSAIDs and antimicrobial drugs with
improved efﬁcacy and better toxicity proﬁle (Cohen, 1992).O
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Scheme 1 Synthesis of novel 3-(2-aminoethyl)-2-methylquinazolin-
functionalities (1–29).
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one derivatives bearing urea, thiourea and sulphonamide functionalities. Arabian JoIn medicinal chemistry quinazolin-4(3H)-one is a basic unit
found in various naturally occurring bioactive alkaloids such
as febrifugine, isofebrifugine, vasicinone, echinozolinone, etc.
(Mhaske and Argade, 2006) and also the literature survey
revealed that the presence of substitution at position 2 as well
as at position 3 in it has been reported to be associated with the
diverse range of pharmacological activities like antimicrobial
(Grover and Kini, 2006; Nanda et al., 2007; Panneerselvam
et al., 2009; Mohamed et al., 2010), analgesic/anti-inﬂamma-
tory (Maggio et al., 2001; Kumar et al., 2003; Alagarsamy
et al., 2003a,b; Chao et al., 1999), CNS depressant/anticonvul-
sant (Srivastava and Kumar, 2002, 2004), anti-cancer (Kamal
et al., 2010) and anti-HIV, anti-viral/Cytotoxic (Dinakaran
et al., 2003).O
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Table 1 Anti-inﬂammatory activity of novel 3-(2-amino-
ethyl)-2-methylquinazolin-4(3H)-one derivatives containing
urea, thiourea and sulphonamide functionalities.
Compounds % Inhibition at 10 lM
TNF-a IL-6
1 0 0
2 0 0
3 84 92
4 62 73
5 8 11
6 70 81
7 17 25
8 20 42
9 65 75
10 22 31
11 31 45
12 0 16
13 52 67
14 20 35
15 28 42
16 78 89
17 0 11
18 72 83
19 0 14
20 50 62
21 16 32
22 0 0
23 0 0
24 25 38
25 8 17
26 52 66
27 18 25
28 0 10
29 0 0
Dexamethasone (1 lg/ml) 75 84
Synthesis of novel 2-methylquinazolin-4(3H)-one derivatives 3In addition the importance of functionalities like urea, thio-
urea and sulphonamide in medicinal chemistry is well recog-
nized in the literature and the presence of which is often a
major importance to activity. Quinazolinone bearing urea func-
tionality have sedative-hypnotic/anticonvulsant/cytotoxicity/
anti-HIV-1/antimicrobial/CNS depressant activities (Kashaw
et al., 2008, 2009, 2011) and thiourea functionality have
analgesic/anti-inﬂammatory/antibacterial (Alagarsamy et al.,
2003a,b, 2005) and anticonvulsant /analgesic/cytotoxic/ anti-
microbial activities (Suresha et al., 2011) while quinazolinone
bearing sulphonamide functionality have anti inﬂammatory
and antimicrobial activities (Venkataraman et al., 2010; Patel
and Patel, 2010). Moreover, the potential of 2-methylquinazo-
lin-4(3H)-one derivatives bearing urea, thiourea and sulphona-
mide functionalities as to their anti-inﬂammatory activity
hitherto remained untested.
Motivated by the aforementioned literature and in persis-
tence of our earlier work on different heterocyclic derivatives
bearing urea, thiourea and sulphonamide functionalities
(Keche et al., 2012a,b; Tale et al., 2011a,b), we envisioned
our approach towards design and synthesis of novel structur-
ally diverse series of 2-methylquinazolin-4(3H)-one having
urea, thiourea and sulphonamide functionalities at position
3, for their anti-inﬂammatory and antimicrobial activity.
Therefore, a single molecule containing more than one phar-
macophore, each with different mode of action could be bene-
ﬁcial for the treatment of inﬂammation and microbial diseases.
2. Results and discussion
2.1. Chemistry
Our synthetic strategy for a novel series of 2-methylquinazolin-
4(3H)-one derivatives (1–29) bearing urea, thiourea and sulph-
onamide functionalities is illustrated in Scheme 1. The key
intermediate 6,7-dimethoxy-2-methyl-4H-benzo[d] [1,3] oxa-
zin-4-one 1 was synthesized by the reaction of 3,4-dimethoxy-
anthranilic acid with acetic anhydride in 78% yield. The
reaction of 1 with 1,2-ethylenediamine at reﬂux temperature
for 2 h afforded 3-(2-aminoethyl)-6,7-dimethoxy-2-methylqui-
nazolin-4(3H)-one (2) in 55% yield.
Having secured parent 3-(2-aminoethyl)-6,7-dimethoxy-2-
methylquinazolin-4(3H)-one (2) in good yield, next, the desired
3-(2-aminoethyl)-2-methylquinazolin-4(3H)-one derivatives
bearing urea (3–12), thiourea (13–22) and sulphonamide (23–
29) functionalities were synthesized in good to high yields by
reacting 2 with appropriate arylisocyanates, arylisothiocya-
nates and sulphonyl chloride respectively at room temperature
under mild conditions. The purity of the compounds was
checked by TLC and HPLC. Spectral data 1H NMR, IR
and MS of the newly synthesized compounds 1–29 were in full
agreement with their proposed structures.
2.2. Biology
The synthesized compounds 1–29 were evaluated for in vitro
anti-inﬂammatory activity against the pro-inﬂammatory cyto-
kines (TNF-a and IL-6) by TNF-a and IL-6 inhibition assay
(Hwang et al., 1993) and antimicrobial activity against various
Gram-positive, Gram-negative bacteria and fungal strains by
using the agar well diffusion method with little modiﬁcationsPlease cite this article in press as: Keche, A.P., Kamble, V.M. Synthesis and anti-inﬂa
one derivatives bearing urea, thiourea and sulphonamide functionalities. Arabian Jo(Sridhar et al., 2004). Anti-inﬂammatory, antibacterial and
antifungal activities of 2-methylquinazolin-4(3H)-one deriva-
tives have been presented in Tables 1–3 and some interesting
trend was observed as the lipophilicity as well as nature of
the substituent presents on benzene ring of ureido, thioureido
and sulphonamide terminus affecting the biological activity of
the synthesized analogues.
2.2.1. Anti-inﬂammatory activity
As can be seen from Table 1, compounds 3 and 16 exhibited
the higher TNF-a (84% and 78%) as well as IL-6 (92% and
89%) inhibitory activity as compared to the standard dexa-
methasone but at higher concentration (10 lM) and found to
be potent anti-inﬂammatory agents while compounds 4, 6, 9
and 18 exhibited comparable TNF-a (62%–72%) and IL-6
(73%–83%) inhibitory activity. Compounds 13, 20 and 26
exhibited moderate TNF-a (50%–52%) and IL-6 (62%–
67%) inhibitory activity and rest of the compounds show very
low to no activity at the same level of concentration (10 lM).
It is to be noted that all these active compounds viz. 3, 4, 6, 9,
16 and 18 are either from urea or thiourea series, surprisingly
only compound 26 having Cl at ortho and CF3 at para posi-
tion on the benzene ring of sulphonamide terminus from the
corresponding sulphonamide series was found to be moder-
ately effective against TNF-a (52%) or IL-6 (66%) and rest
are almost very low to no active. This ﬁnding implicates thatmmatory and antimicrobial activities of some novel 2-methylquinazolin-4(3H)-
urnal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.10.025
Table 2 Antibacterial activity of novel 3-(2-aminoethyl)-2-methylquinazolin-4(3H)-one derivatives containing urea, thiourea and
sulphonamide functionalities. (MIC a values lg/ml).
Compounds Gram-positive Gram-negative
Staphylococcus aureus Bacillus subtilis Escherichia coli Salmonella typhimurium
1 – – – –
2 – – – –
3 75 60 80 75
4 80 75 60 70
5 55 65 50 60
6 80 80 65 90
7 15 15 15 20
8 55 50 65 60
9 70 80 65 75
10 15 10 10 10
11 60 55 50 50
12 30 25 30 30
13 110 100 120 110
14 90 80 75 90
15 35 40 30 35
16 110 – – –
17 90 110 115 100
18 75 90 90 80
19 65 75 60 55
20 – – – –
21 40 45 45 50
22 70 80 65 75
23 20 20 15 25
24 65 70 60 60
25 15 10 15 10
26 60 65 55 70
27 85 100 75 90
28 10 15 10 10
29 60 50 70 65
Ciproﬂoxacin 20 15 15 20
–: No activity was observed up to 200 lg/ml.
a Values are the average of three readings.
4 A.P. Keche, V.M. Kamblethe presence of special chemical space viz. urea or thiourea in
the novel 2-methylquinazolin-4(3H)-one scaffold is of immense
importance in order to have moderate to potent anti-
inﬂammatory activity.
The structure–activity relationship of these newly synthe-
sized compounds is represented in Table 1 and it can be seen
that anti-inﬂammatory activity can be attributed to the pres-
ence of urea or thiourea functionality in 2-methylquinazolin-
4(3H)-one scaffold as the most potent compounds 3, 4, 6, 9,
16 and 18 are the derivatives bearing either urea or thiourea
moiety and similar to our previously reported work [31] in this
study also none of the members from the corresponding sulph-
onamide series (compounds 23–29) were found to be a potent
anti-inﬂammatory agent. Here it is to be noted that the nature
of the substituent present on the benzene ring of ureido or
thioureido terminus is found to have strong inﬂuence on the
activity which can be conﬁrmed by the fact that the presence
of lipophilic H-bond acceptor type functionalities like F, CF3
or OCF3 at ortho position is foremost to the moderately
potent anti-inﬂammatory compounds 3, 4, 6, 9, 16 and 18.
The compounds 3, 6 and 9 having F, CF3 and OCF3 at ortho
position on the benzene ring of ureido terminus exhibited 84%
- 65% TNF-a and 92% - 75% IL-6 inhibitory activity respec-
tively and proved to be a moderately potent anti-inﬂammatoryPlease cite this article in press as: Keche, A.P., Kamble, V.M. Synthesis and anti-inﬂ
one derivatives bearing urea, thiourea and sulphonamide functionalities. Arabian Joagent, while the presence of same substituent at para position
on the benzene ring of ureido terminus leading to compounds
7 and 10 was found to have low TNF-a (17%–22%) and IL-6
(25%–31%) inhibitory activity. Similarly, the compounds 16
and 18 having F and CF3 at ortho position on the benzene ring
of thioureido terminus exhibited 78%–72% TNF-a and 89%–
83% IL-6 inhibitory activity and proved to be a moderately
potent anti-inﬂammatory agent, while the presence of same
substituent at meta position on the benzene ring of thioureido
terminus leading to compounds 17 and 19 was found to be
inactive against TNF-a and very low IL-6 (11%–14%) inhibi-
tory activity. Also it is to be noted that the electron donating
group like OMe at ortho position on the benzene ring of thio-
ureido terminus in compound 13 and lipophilic H-bond accep-
tor type group like di-CF3 at meta position on the benzene ring
of thioureido terminus in compound 20 show moderate TNF-a
(52%–50%) and IL-6 (67%–62%) inhibitory activity, while
OMe at meta and para position on the benzene ring of thioure-
ido terminus leading to compound 14 and 15 showed low
TNF-a (20%–28%) and IL-6 (35%–42%) inhibitory activity.
As of now, though we have no concrete evidence in hand in
support of the actual role of urea or thiourea functionalities
on this activity, we can at least speculate that the H-bond
donor ability of the urea or thiourea (not present inammatory and antimicrobial activities of some novel 2-methylquinazolin-4(3H)-
urnal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.10.025
Table 3 Antifungal activity of novel 3-(2-aminoethyl)-2-methylquinazolin-4(3H)-one derivatives containing urea, thiourea and
sulphonamide functionalities (MIC a values lg/ml).
Compounds Candida albicans Aspergillus niger Fusarium solani Aspergillus ﬂavus
1 – – – –
2 – – – –
3 80 75 90 70
4 65 70 80 75
5 65 50 60 70
6 90 75 90 80
7 15 20 10 20
8 65 60 75 55
9 80 75 65 85
10 15 15 10 15
11 80 60 55 60
12 20 20 15 30
13 120 90 110 100
14 90 85 70 80
15 35 35 30 40
16 130 – – –
17 90 100 105 90
18 75 80 90 80
19 75 60 55 60
20 – – 120 –
21 40 45 40 45
22 80 90 75 65
23 25 20 25 25
24 60 65 80 80
25 20 15 15 25
26 70 65 75 60
27 70 75 65 80
28 15 10 10 15
29 60 55 60 65
Miconazole 20 15 15 20
–: No activity was observed up to 200 lg/ml.
a Values are the average of three readings.
Synthesis of novel 2-methylquinazolin-4(3H)-one derivatives 5sulphonamide framework) along with the electronic effect of
ortho or para substituent might be responsible for their anti-
inﬂammatory activity.
2.2.2. Antimicrobial activity
The antibacterial activity data are represented in Table 2. As
shown in our results, some analogues of this series were found
to have even more potency than the standard drug ciproﬂoxa-
cin while some of them have comparable potency.
The compounds 10, 25 and 28 exhibited comparable or
higher antibacterial activities than ciproﬂoxacin against each
strain tested while compounds 7, 12, 15, 21 and 23 showed
moderate to comparable antibacterial activities than ciproﬂox-
acin according to the strain tested. Other compounds exhibited
lower to no activities than ciproﬂoxacin.
The compound 10 bearing OCF3 at para position on the
benzene ring of ureido terminus is 1.3-fold more potent against
Staphylococcus aureus (MTCC 96), Bacillus subtilis (MTCC
441) and Escherichia coli (MTCC 443) while 1.5-fold more
potent against Salmonella typhimurium (MTCC 98) than stan-
dard drug ciproﬂoxacin and found to be the most potent anti-
bacterial agent, but compound 7 bearing CF3 at para position
on the benzene ring of ureido terminus is almost 1.3-fold more
potent against S.s aureus (MTCC 96) and comparable to otherPlease cite this article in press as: Keche, A.P., Kamble, V.M. Synthesis and anti-inﬂa
one derivatives bearing urea, thiourea and sulphonamide functionalities. Arabian Jobacterial strains. Compound 25 bearing Br at ortho and CF3 at
para position on the benzene ring of sulphonamide terminus is
1.3-fold more potent against S.s aureus (MTCC 96), B.s subtilis
(MTCC 441) while 1.5-fold more potent against S. typhimuri-
um (MTCC 98) than standard drug ciproﬂoxacin. Interestingly
compound 28 bearing OMe at para and meta position on the
benzene ring of sulphonamide terminus is 1.5-fold more potent
against S.s aureus (MTCC 96) and S. typhimurium (MTCC 98)
while 1.3-fold more potent against E.s coli (MTCC 443) than
standard drug ciproﬂoxacin.
Concerning the antifungal activity data represented in
Table 3, compounds 10 and 28 exhibited higher antifungal
activities, while compounds 7, 12, 15, 21, 23 and 25 exhibited
moderate to comparable antifungal activities than miconazole
according to the strain tested.
The compound 10 is 1.3-fold more potent against Candida
albicans (MTCC 227) and Aspergillus ﬂavus (MTCC 277) while
1.5-fold more potent against Fusarium solani (MTCC 350) and
compound 7 is almost 1.3-fold more potent against C. albicans
(MTCC 227) and 1.5-fold more potent against F.s solani
(MTCC 350) than standard drug miconazole. Interestingly
compound 28 is 1.3-fold more potent against C. albicans
(MTCC 227) and Aspergillus ﬂavus (MTCC 277) while 1.5-fold
more potent against Aspergillus niger (MTCC 281), F.s solanimmatory and antimicrobial activities of some novel 2-methylquinazolin-4(3H)-
urnal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.10.025
6 A.P. Keche, V.M. Kamble(MTCC 350) than standard drug miconazole and found to be
the most potent antifungal agent.
From the above activity data we come to a conclusion that,
the compound 10 bearing OCF3 at para position on the ben-
zene ring of ureido terminus and the compound 28 bearing
OMe at para and meta position on the benzene ring of sulph-
onamide terminus are the most potent antimicrobial agents
followed by compound 25 bearing Br at ortho and CF3 at para
position on the benzene ring of sulphonamide terminus. The
high potency or comparable activity of compounds 7, 10, 23
and 25 may be attributed to the presence of lipophilic H-bond
acceptor type groups like CF3, OCF3, Cl, and Br at para posi-
tion on the benzene ring of urea and sulphonamide functional-
ities while compounds 12 and 28 may be due to the presence of
electron donating groups like OMe or Me at meta and para
position on the benzene ring of urea and sulphonamide
functionalities.
It is clear from our results (Table 2 vs. Table 3) that the
SAR of 2-methylquinazolin-4(3H)-one derivatives bearing
urea, thiourea and sulphonamide functionalities for antibacte-
rial activity strongly correlates with their SAR of antifungal
activity. To our surprise, none of the most active anti-inﬂam-
matory agents 3, 4, 6, 9, 16 and 18 were found to be active anti-
bacterial or antifungal agents against all the bacteria or fungi
screened but importantly indicate the low toxicity associated
with them and should be considered as ideal anti-inﬂammatory
agents.3. Conclusion
In conclusion, the intention of the present study was to synthe-
size and investigate the anti-inﬂammatory and antimicrobial
activities of novel structurally diverse 2-methylquinazolin-
4(3H)-one derivatives bearing urea, thiourea and sulphona-
mide functionalities with the hope of discovering a new struc-
ture leads serving as an anti-inﬂammatory or antimicrobial
agents. With little exception, overall it has been observed that
the urea or thiourea was found to be favourable in structural
feature for the anti-inﬂammatory activity, while no particular
trend was observed for antimicrobial activity. Thus the pres-
ence of substituents such as F, CF3 or OCF3 at ortho position
on the benzene ring of urea or thiourea terminus was found to
have strong relevance to the anti-inﬂammatory activity while
CF3, OCF3, Cl, and Br at para position and OMe or Me at
meta and para position on the benzene ring of urea, thiourea
and sulphonamide terminus were found to be effective antimi-
crobial agents. Thus the nature and position of the substituent
were found to be crucial to improve the activity.
4. Experimental
4.1. General
All commercial chemicals and solvents are of reagent grade and
were used without further puriﬁcation. The thin layer chroma-
tography was performed on Merck pre-coated silica gel 60 F254
plates, with visualization under UV light. 1H NMR spectra
were recorded with a Bruker 300 MHz AVANCE instrument
and J values are in Hertz and chemical shifts (d) are reported
in ppm relative to internal tetramethylsilane. IR (Perkin-ElmerPlease cite this article in press as: Keche, A.P., Kamble, V.M. Synthesis and anti-inﬂ
one derivatives bearing urea, thiourea and sulphonamide functionalities. Arabian JoFT-IR) spectroscopic technique. The mass spectra were mea-
sured with Thermo Finnigan-TSQ Quantum Ultra (triple
Quad). The purity of all compounds was determined by HPLC
(Waters 2695 Alliance) using column Kromasil C18, solvent
acetonitrile & buffer (0.01 M ammonium acetate + 0.5%
triethylamine, pH 5.0 with acetic acid). Melting points were
determined with a (PEW-340MP) melting point apparatus
and are uncorrected.
4.2. Synthesis of 6,7-dimethoxy-2-methyl-4H-benzo[d] [1,3]
oxazin-4-one (1)
Anthranilic acid (1 equiv) was taken in acetic anhydride
(excess) and reﬂuxed under anhydrous condition for 4 h and
progress of reaction monitored by TLC in ethyl acetate–petro-
leum ether (2:8). After completion of reaction, excess of acetic
anhydride was then distilled off under reduced pressure and
the viscous reaction mass triturated in petroleum ether and
obtained solid was ﬁltered to afford title compound as white
solid. Yield 78%, mp 178–180 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 7.32 (s, 1H), 7.02 (s, 1H), 3.85 (s, 3H),
3.81 (s, 3H), 2.10 (s, 3H); MS (APCI); m/z 222.1[M+H]+;
HPLC; 98%.
4.3. Synthesis of 3-(2-aminoethyl)-6,7-dimethoxy-2-
methylquinazolin-4(3H)-one (2)
A mixture of 6,7-dimethoxy-2-methyl-4H-benzo[d] [1,3] oxa-
zin-4-one (1) (1 equiv) and 1,2-ethylenediamine (excess) was
directly heated at 120 C for 2 h with continuous stirring and
reaction monitored by TLC in ethyl acetate–petroleum ether
(4:6). The reaction mixture was then poured in ice cold water
and extracted with ethyl acetate. Organic layer was washed
by fresh water and brine, dried on Na2SO4 and concentrated
under reduced pressure to afford crude product, which was
puriﬁed by silica gel (100–200 #) column chromatography in
30% ethyl acetate petroleum ether as eluent to obtain a title
compound as reddish solid. Yield 55%, mp 253–255 C; 1H
NMR (DMSO-d6, 300 MHz, d ppm): 7.51 (s, 1H), 7.40 (s,
1H), 4.37 (t, J = 6.0 Hz, 2H), 3.95 (s, 3H), 3.92 (s, 3H),
3.22–3.26 (m, 2H), 3.07 (brs, 2H), 2.92 (s, 3H); MS (APCI);
m/z 264.4[M+H]+; HPLC; 95%.
4.4. General procedure to synthesize compounds 3–12
To a solution of 3-(2-aminoethyl)-6,7-dimethoxy-2-methylqui-
nazolin-4(3H)-one (2) (1 equiv) in THF (10 ml) different
substituted isocyanates (1.1 equiv) were added. Resulting reac-
tion mixture was stirred at room temperature for 1–2 h and
progress of reaction monitored by TLC in ethyl acetate- petro-
leum ether (4:6). Resulting reaction mixture was diluted with
hexane and obtained solid was ﬁltered to afford crude product,
which was puriﬁed by silica gel (100–200 #) ﬂash column chro-
matography in ethyl acetate petroleum ether (40:60) as eluent
to obtain a title compound in moderate to good yield.
4.4.1. Synthesis of 1-(2-(6,7-dimethoxy-2-methyl-4-
oxoquinazolin-3(4H)-yl) ethyl)-3-(2-ﬂuorophenyl) urea (3)
Yield 81%, mp 232–234 C; 1H NMR (DMSO-d6, 300 MHz, d
ppm): 8.33–8.35 (m, 1H), 7.99 (td, J= 8.3, 1.5 Hz, 1H), 7.40ammatory and antimicrobial activities of some novel 2-methylquinazolin-4(3H)-
urnal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.10.025
Synthesis of novel 2-methylquinazolin-4(3H)-one derivatives 7(s, 1H), 7.11–7.19 (m, 1H), 7.01–7.08 (m, 2H), 6.88–6.96 (m,
1H), 6.79 (t, J = 6.0 Hz, 1H), 4.12 (t, J = 7.6 Hz, 2H), 3.86
(s, 6H), 3.37–3.46 (m, 2H), 2.58 (s, 3H); IR (KBr) mmax/cm–1
3400 (N–H str.), 3149 (C–H), 1533 (C‚O urea), 1245 (C–O),
1193 (C–F), 1064 (C–H), 899 (C–N); MS (APCI); m/z
398.92[MH]; HPLC; 97%.
4.4.2. Synthesis of 1-(3-chloro-2-ﬂuorophenyl)-3-(2-(6,7-
dimethoxy-2-methyl-4-oxoquinazolin-3(4H)-yl) ethyl) urea (4)
White solid, Yield 80%, mp 245–247 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 8.53 (d, J = 1.9 Hz, 1H), 7.88–8.23 (m,
1H), 7.39 (s, 1H), 7.02–7.24 (m, 3H), 6.83 (t, J = 6.0 Hz,
1H), 4.13 (t, J = 6.2 Hz, 2H), 3.86 (s, 6H), 3.36–3.59
(m, 2H), 2.58 (s, 3H); IR (KBr) mmax/cm1 3450 (N-H str),
3149 (C–H), 1637 (C‚O urea), 1366 (C–F), 1230 (C–O),
1173 (C–H), 825 (C–N), 615 (C–Cl); MS (APCI); m/z
432.83[MH]; HPLC; 99%.
4.4.3. Synthesis of 1-(2-(6,7-dimethoxy-2-methyl-4-
oxoquinazolin-3(4H)-yl) ethyl)-3-(5-ﬂuoro-2-methylphenyl)
urea (5)
White solid, Yield 83%, mp 244–246 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 7.75 (s, 1H), 7.54–7.61 (m, 1H), 7.35 (s, 1H),
6.96–7.08 (m, 2H), 6.84 (brs, 1H), 6.64 (t, J = 6.0 Hz, 1H), 4.03–
4.11 (m, 2H), 3.99 (s, 6H), 3.33–3.42 (m, 2H), 3.21 (brs, 3H), 2.53
(s, 3H); IR (KBr) mmax/cm–1 3400 (N–H str), 3153 (C–H), 1561
(C‚O urea), 1300 (C–F), 1240 (C–O), 1173 (C–H), 751 (C–N);
MS (APCI); m/z 412.92[MH]; HPLC; 96%.
4.4.4. Synthesis of 1-(2-(6,7-dimethoxy-2-methyl-4-
oxoquinazolin-3(4H)-yl) ethyl)-3-(2-(triﬂuoromethyl) phenyl)
urea (6)
White solid, Yield 79%, mp 243–245 C; 1H NMR
(CDCl3 + Drop of MeOD, 300 MHz, d ppm): 7.55 (s, 1H),
7.49–7.50 (m, 3H), 7.35 (s, 1H), 7.11–7.19 (m, 1H), 7.02 (s,
1H), 6.48 (t, J = 6.0 Hz, 1H), 4.28 (t, J = 6.6 Hz, 2H), 3.99
(s, 3H), 3.98 (s, 3H), 3.57–3.59 (m, 2H), 2.71 (s, 3H); IR
(KBr) mmax/cm–1 3400 (N–H str), 3153 (C–H), 1561 (C‚O
urea), 1300 (C–F), 1259 (C–O), 1173 (C–H), 751 (C–N); MS
(APCI); m/z 451.2[M+H]+; HPLC; 99%.
4.4.5. Synthesis of 1-(2-(6,7-dimethoxy-2-methyl-4-
oxoquinazolin-3(4H)-yl) ethyl)-3-(4-(triﬂuoromethyl) phenyl)
urea (7)
White solid, Yield 80%, mp 220–223 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 8.05 (s, 1H), 7.48 (s, 5H), 7.02 (s, 1H), 5.92
(t, J = 6 Hz, 1H), 4.3 (t, J = 6.6 Hz, 2H), 3.99 (s, 3H), 3.98 (s,
3H), 3.56–3.62 (m, 2H), 2.72 (s, 3H); IR (KBr) mmax/cm–1
3400 (N–H str), 3153 (C–H), 1561 (C‚O urea), 1300 (C–F),
1241 (C–O), 1173 (C–H), 751 (C–N); MS (APCI); m/z
451.2[M+H]+; HPLC; 97%.
4.4.6. Synthesis of 1-(2-chloro-5-(triﬂuoromethyl) phenyl)-3-
(2-(6,7-dimethoxy-2-methyl-4-oxoquinazolin-3(4H)-yl) ethyl)
urea (8)
White solid, Yield 78%, mp 256–258 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 8.04 (brs, 1H), 7.59–7.74 (m, 2H), 7.36–7.49
(m, 3H), 6.67 (t, J = 6.0 Hz, 1H), 4.21 (t, J = 5.9 Hz, 2H),
3.95 (s, 3H), 3.92 (s, 3H), 3.28–3.41 (m, 2H), 2.59 (s, 3H); IR
(KBr) mmax/cm–1 3400 (N-H str), 3153 (C–H), 1561 (C‚OPlease cite this article in press as: Keche, A.P., Kamble, V.M. Synthesis and anti-inﬂa
one derivatives bearing urea, thiourea and sulphonamide functionalities. Arabian Jourea), 1300 (C–F), 1223 (C–O), 1173 (C–H), 751 (C–N), 615
(C–Cl); MS (APCI); m/z 485.07[M+H]+; HPLC; 97%.
4.4.7. Synthesis of 1-(2-(6,7-dimethoxy-2-methyl-4-oxoquin
azolin-3(4H)-yl) ethyl)-3-(2-(triﬂuoromethoxy) phenyl) urea
(9)
White solid, Yield 80%, mp 246–249 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 8.21 (s, 1H), 8.10 (dd, J = 8.3, 1.5 Hz, 1H),
7.40 (s, 1H), 7.17–7.35 (m, 2H), 6.96–7.14 (m, 2H), 6.64 (t,
J = 6.0 Hz, 1H), 4.12 (t, J = 6.0 Hz, 2H), 3.95 (s, 3H), 3.86
(s, 3H), 3.37–3.60 (m, 2H), 2.57 (s, 3H); IR (KBr) mmax/cm–
1 3400 (N–H str), 3153 (C–H), 1561 (C‚O urea), 1265 (C–
O), 1300 (C–F), 1173 (C–H), 751 (C–N); MS (APCI); m/z
464.92[MH]; HPLC; 98%.
4.4.8. Synthesis of 1-(2-(6, 7-dimethoxy-2-methyl-4-oxoquin
azolin-3(4H)-yl) ethyl)-3-(4-(triﬂuoromethoxy) phenyl) urea
(10)
White solid, Yield 78%, mp 228–230 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 8.82 (s, 1H), 7.39–7.48 (m, 3H), 7.20 (d,
J = 8.3 Hz, 2H), 7.04 (s, 1H), 6.45 (t, J = 6.0 Hz, 1H), 4.12
(t, J = 6.4 Hz, 2H), 3.95 (s, 3H), 3.86 (s, 3H), 3.39–3.49 (m,
2H), 2.59 (s, 3H); IR (KBr) mmax/cm–1 3400 (N–H str), 3153
(C–H), 1561 (C‚O urea), 1300 (C–F), 1193 (C–O), 1173 (C–
H), 751 (C–N); MS (APCI); m/z 464.93[MH]; HPLC; 98%.
4.4.9. Synthesis of 1-(2-(6, 7-dimethoxy-2-methyl-4-oxoquin
azolin-3(4H)-yl) ethyl)-3-(4-isopropylphenyl) urea (11)
White solid, Yield 83%, mp 204–206 C; 1H NMR (DMSO-d6,
300 MHz, d ppm):): 8.45 (s, 1H), 7.40 (s, 1H), 7.25 (d,
J = 8.7 Hz, 2H), 7.03–7.09 (m, 3H), 6.32 (t, J = 6.0 Hz,
1H), 4.11 (t, J = 6.4 Hz, 2H), 3.95 (s, 3H), 3.86 (s, 3H),
3.32–3.41 (m, 2H), 2.71–2.83 (m, 1H), 2.53 (s, 3H), 1.12–1.25
(m, 6H); IR (KBr) mmax/cm–1 3435 (N–H str), 3148 (C–H),
1637 (C‚O urea), 1236 (C–O), 1173 (C–H), 825 (C–N); MS
(APCI); m/z 422.87[M–H]; HPLC; 98%.
4.4.10. Synthesis of 1-(2-(6,7-dimethoxy-2-methyl-4-oxoquin
azolin-3(4H)-yl) ethyl)-3-(3, 4-dimethylphenyl) urea (12)
White solid, Yield 83%, mp 218–220 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 8.35 (s, 1H), 7.40 (s, 1H), 7.02–7.14 (m, 3H),
6.92–6.99 (m, 1H), 6.30 (t, J = 6.0 Hz, 1H), 4.11 (t,
J = 6.2 Hz, 2H), 3.95 (s, 3H), 3.86 (s, 3H), 3.42–3.50 (m,
2H), 2.53 (s, 3H), 2.07–2.18 (m, 6H); IR (KBr) mmax/cm–1
3400 (N–H str), 3153 (C–H), 1561 (C‚O urea), 1260 (C–O),
1173 (C–H), 751 (C–N); MS (APCI); m/z 411.07[M+H]+;
HPLC; 98%.
4.5. General procedure to synthesize compounds A13–A22
To a solution of 3-(2-aminoethyl)-6,7-dimethoxy-2-methylqui-
nazolin-4(3H)-one (2) (1 equiv) in THF (10 ml), different
substituted isothiocyanates (1.1 equiv) were added. Resulting
reaction mixture was stirred at room temperature for 1–2 h
and progress of reaction monitored by TLC in ethyl acetate-
petroleum ether (4:6). Resulting reaction mixture was diluted
with hexane and obtained solid was ﬁltered to afford crude
product, which was puriﬁed by silica gel (100–200 #) ﬂash col-
umn chromatography in ethyl acetate petroleum ether (40:60)
as eluent to obtain a title compound in moderate to good yield.mmatory and antimicrobial activities of some novel 2-methylquinazolin-4(3H)-
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8 A.P. Keche, V.M. Kamble4.5.1. Synthesis of 1-[2-(6,7-Dimethoxy-2-methyl-4-oxo-4H-
quinazolin-3-yl)-ethyl]-3-(2-methoxy-phenyl)-thiourea (13)
White solid, Yield 86%, mp 178–180 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 9.00 (s, 1H), 7.91 (brs, 1H), 7.52 (d, 1H,
J= 6.4 Hz), 7.39 (s, 1H), 7.10–7.27 (m, 1H), 7.06 (s, 2H),
6.89 (t, J = 7.6 Hz, 1H), 4.20 (t, J = 5.9 Hz, 2H), 3.87 (s,
6H), 3.60–3.80 (m, 5H), 2.61 (s, 3H); IR (KBr) mmax/cm–1
3435 (N–H str), 3149 (C–H), 1561 (C‚O), 1448 (C‚S),
1225 (C–O), 1172 (C–H), 768 (C–N); MS (APCI); m/z 427.4[
MH]; HPLC; 99%.
4.5.2. 1-[2-(6,7-Dimethoxy-2-methyl-4-oxo-4H-quinazolin-3-
yl)-ethyl]-3-(3-methoxy-phenyl)-thiourea (14)
White solid, Yield 84%, mp 181–183 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 9.58 (s, 1H), 7.89 (brs, 1H), 7.34 (s, 1H),
7.06–7.18 (m, 1H), 7.00 (s, 1H), 6.87 (brs, 1H), 6.76 (d, 1H,
J= 7.2 Hz), 6.65 (t, 1H, J= 7.6 Hz), 4.20 (t, J = 5.9 Hz,
2H), 3.86 (s, 6H), 3.54–3.82 (m, 5H), 2.55 (s, 3H); IR (KBr)
mmax/cm–1 3435 (N–H str), 3148 (C–H), 1637 (C‚O), 1448
(C‚S), 1244 (C–O), 1172 (C–H), 768 (C–N); MS (APCI);
m/z 427.4[M+H]+; HPLC; 98%.
4.5.3. Synthesis of 1-[2-(6,7-Dimethoxy-2-methyl-4-oxo-4H-
quinazolin-3-yl)-ethyl]-3-(4-methoxy-phenyl)-thiourea (15)
White solid, Yield 87%, mp 176–178 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 9.43 (s, 1H), 7.69 (brs, 1H), 7.39 (s, 1H),
7.15 (d, 2H, J= 9.1 Hz), 6.86 (d, 2H, J= 9.1 Hz), 6.65 (t,
1H, J= 7.6 Hz), 4.21 (t, J = 5.9 Hz, 2H), 3.86 (s, 6H), 3.69–
3.82 (m, 5H), 2.60 (s, 3H); IR (KBr) mmax/cm–1 3435 (N–H
str), 3149 (C–H), 1561 (C‚O), 1448 (C‚S), 1195 (C–O),
1172 (C–H), 768 (C–N); MS (APCI); m/z 427.6[MH];
HPLC; 98%.
4.5.4. Synthesis of 1-[2-(6, 7-Dimethoxy-2-methyl-4-oxo-4H-
quinazolin-3-yl)-ethyl]-3-(2-ﬂuoro-phenyl)-thiourea (16)
White solid, Yield 83%, mp 173–175 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 9.36 (s, 1H), 8.01 (brs, 1H), 7.44 (s, 1H),
7.39 (d, 1H, J= 2.7 Hz), 7.22–7.26 (m, 2H), 7.14 (t, 1H,
J= 1.8 Hz), 7.05 (s, 1H), 4.20 (t, J = 6 Hz, 2H), 3.87 (s,
3H), 3.84 (s, 3H), 3.77–3.79 (m, 2H), 2.59 (s, 3H); IR (KBr)
mmax/cm–1 3395 (N–H str.), 3154 (C–H), 1690 (C‚O), 1540
(C‚S), 1355 (C–F), 1203 (C–O), 1023 (C–H), 762 (C–N);
MS (APCI); m/z 417.53[M+H]+; HPLC; 99%.
4.5.5. Synthesis of 11-[2-(6, 7-Dimethoxy-2-methyl-4-oxo-4H-
quinazolin-3-yl)-ethyl]-3-(3-ﬂuoro-phenyl)-thiourea (17)
White solid, Yield 86%, mp 179–182 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 9.78 (s, 1H), 8.10 (brs, 1H), 7.39 (s, 1H),
7.27–7.34 (m, 2H), 7.05–7.09 (m, 2H), 6.94 (t, 1H,
J= 6.3 Hz), 4.23 (t, J = 5.7 Hz, 2H), 3.87 (s, 3H), 3.84 (s,
3H), 3.77–3.80 (m, 2H), 2.59 (s, 3H); IR (KBr) mmax/cm–1
3395 (N–H str.), 3154 (C–H), 1650 (C‚O), 1540 (C‚S),
1355 (C–F), 1230 (C–O), 1023 (C–H), 762 (C–N); MS (APCI);
m/z 417.47[M+H]+; HPLC; 99%.
4.5.6. Synthesis of 1-[2-(6, 7-Dimethoxy-2-methyl-4-oxo-4H-
quinazolin-3-yl)-ethyl]-3-(2-triﬂuoromethyl-phenyl)-thiourea
(18)
White solid, Yield 85%, mp 183–185 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 9.86 (s, 1H), 8.17 (brs, 1H), 7.82 (s, 1H),Please cite this article in press as: Keche, A.P., Kamble, V.M. Synthesis and anti-inﬂ
one derivatives bearing urea, thiourea and sulphonamide functionalities. Arabian Jo7.57–7.65 (m, 1H), 7.51 (t, 1H, J= 1.8 Hz), 7.37–7.46 (m,
2H), 7.04 (s, 1H), 4.24 (t, J = 5.9 Hz, 2H), 3.87 (s, 3H), 3.84
(s, 3H), 3.77–3.79 (m, 2H), 2.60 (s, 3H); IR (KBr) mmax/cm–
1 3435 (N–H str.), 3100 (C–H), 1637 (C‚O urea), 1530
(C‚S), 1372 (C–F), 1259 (C–O), 1200 (C–H), 902 (C–N);
MS (APCI); m/z 465.25[MH]; HPLC; 97%.
4.5.7. Synthesis of 1-[2-(6, 7-Dimethoxy-2-methyl-4-oxo-4H-
quinazolin-3-yl)-ethyl]-3-(3-triﬂuoromethyl-phenyl)-thiourea
(19)
White solid, Yield 84%, mp 187–189 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 9.22 (s, 1H), 8.15 (brs, 1H), 7.70 (d,
J = 7.6 Hz, 1H), 7.61 (d, J = 7.6 Hz, 1H), 7.42–7.48 (m,
2H), 7.39 (s, 1H), 7.06 (s, 1H), 4.20 (t, J = 5.9 Hz, 2H), 3.87
(s, 3H), 3.85 (s, 3H), 3.78–3.80 (m, 2H), 2.59 (s, 3H); IR
(KBr) mmax/cm–1 3435 (N–H str.), 3100 (C–H), 1603 (C‚O
urea), 1530 (C‚S), 1372 (C–F), 1240 (C–O), 1200 (C–H),
902 (C–N); MS (APCI); m/z 465.17[MH]; HPLC; 98%.
4.5.8. Synthesis of 1-(3, 5-Bis-triﬂuoromethyl-phenyl)-3-[2-(6,
7-dimethoxy-2-methyl-4-oxo-4H-quinazolin-3-yl)-ethyl]-
thiourea (20)
White solid, Yield 84%, mp 181–184 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 10.17 (s, 1H), 8.42 (brs, 1H), 8.15–8.29 (m,
2H), 7.75 (s, 1H), 7.39 (t, 1H, J= 1.8 Hz), 7.06 (s, 1H), 4.25 (t,
J = 6 Hz, 2H), 3.93 (s, 3H), 3.87 (s, 3H), 3.80–3.82 (m, 2H),
2.60 (s, 3H); IR (KBr) mmax/cm–1 3435 (N–H str.), 3100 (C–
H), 1533 (C‚O urea), 1530 (C‚S), 1372 (C–F), 1223 (C–
O), 1200 (C–H), 902 (C–N); MS (APCI); m/z
535.60[M+H]+; HPLC; 98%.
4.5.9. Synthesis of 1-(4-Chloro-phenyl)-3-[2-(6, 7-dimethoxy-
2-methyl-4-oxo-4H-quinazolin-3-yl)-ethyl]-thiourea (21)
White solid, Yield 81%, mp 182–184 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 9.70 (s, 1H), 8.02 (brs, 1H), 7.29–7.50 (m,
5H), 7.05 (s, 1H), 4.22 (t, J = 6 Hz, 2H), 3.94 (s, 3H), 3.87
(s, 3H), 3.73–3.78 (m, 2H), 2.59 (s, 3H); IR (KBr) mmax/cm–
1 3390 (N–H str.), 3137 (C–H), 1561 (C‚O), 1519 (C‚S),
1230 (C–O), 1173 (C–H), 773 (C–N), 615 (C–Cl); MS (APCI);
m/z 433.75[M+H]+; HPLC; 98%.
4.5.10. Synthesis of 1-[2-(6, 7-Dimethoxy-2-methyl-4-oxo-4H-
quinazolin-3-yl)-ethyl]-3-p-tolyl-thiourea (22)
White solid, Yield 85%, mp 176–178 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 9.54 (s, 1H), 7.82 (brs, 1H), 7.40 (s, 1H),
7.04–7.17 (m, 5H), 4.22 (t, J = 5.9 Hz, 2H), 3.87 (s, 3H),
3.85 (s, 3H), 3.29–3.43 (m, 2H), 2.60 (s, 3H), 2.26 (s, 3H); IR
(KBr) mmax/cm–1 3567 (N–H str.), 3137 (C–H), 1690
(C‚O), 1519 (C‚S), 1265 (C–O), 1173 (C–H), 773 (C–N);
MS (APCI); m/z 413[M+H]+; HPLC; 97%.
4.6. General procedure to synthesize compounds A23–A29
To a solution of 3-(2-aminoethyl)-6,7-dimethoxy-2-methylqui-
nazolin-4(3H)-one (2) (1 equiv) in DCM (10 ml), different
substituted sulphonyl chlorides (1.1 equiv) and triethylamine
(1.1 equiv) were added. Resulting reaction mixture was stirred
at room temperature for 1–2 h and progress of reaction mon-
itored by TLC in ethyl acetate- petroleum ether mixture (3:7).
Resulting reaction mixture was diluted with DCM and waterammatory and antimicrobial activities of some novel 2-methylquinazolin-4(3H)-
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brine, dried on Na2SO4 and concentrated under reduced pres-
sure to afford crude product, which was puriﬁed by silica gel
(100–200 #) ﬂash column chromatography in ethyl acetate
petroleum ether (30:70) as eluent to obtain a title compound
in moderate to good yield.
4.6.1. Synthesis of 4-Bromo-N-[2-(6, 7-dimethoxy-2-methyl-4-
oxo-4H-quinazolin-3-yl)-ethyl]-benzenesulphonamide (23)
White solid, Yield 84%, mp 187–189 C; 1H NMR (CDCl3,
300 MHz, d ppm): 8.09 (s, 1H), 7.64–7.70 (m, 4H), 7.35 (s,
1H), 7.05(brs, 1H), 4.06 (brs 2H), 3.89 (s, 3H), 3.86 (s, 3H),
3.16 (brs, 2H), 2.59 (s, 3H); IR (KBr) mmax/cm–1 3435 (N–H
str.), 3142 (C–H), 1533 (C‚O), 1434 (SO2NH), 1236 (C–O),
1168 (C–H), 765 (C–N), 673 (C–Br); MS (APCI); m/z
483.9[M+H]+; HPLC; 97%.
4.6.2. Synthesis of N-[2-(6, 7-Dimethoxy-2-methyl-4-oxo-4H-
quinazolin-3-yl)-ethyl]-4-triﬂuoromethyl-benzenesulphonamide
(24)
White solid, Yield 87%, mp 184–186 C; 1H NMR (CDCl3,
300 MHz, d ppm): 7.94 (d, J = 6.9 Hz, 2H), 7.65 (d,
J = 6.9 Hz, 2H), 7.28 (s, 1H), 6.77 (s, 1H), 6.55(brs, 1H),
4.29 (brs, 2H), 3.92 (s, 6H), 3.49 (brs, 2H), 2.68 (s, 3H); MS
(APCI); IR (KBr) mmax/cm–1 3417 (N–H str), 3147 (C–H),
1560 (C‚O), 1443 (SO2NH), 1355 (C–F), 1260 (C–O), 1159
(C–H), 765 (C–N); m/z 472.3[MH]+; HPLC; 98%.
4.6.3. Synthesis of 2-Bromo-N-[2-(6, 7-dimethoxy-2-methyl-4-
oxo-4H-quinazolin-3-yl)-ethyl]-4-triﬂuoromethyl-
benzenesulphonamide (25)
White solid, Yield 82%, mp 185–187 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 8.24 (d, J = 7.8 Hz, 1H), 7.93 (s, 1H), 7.71
(d, J = 7.5 Hz, 1H), 7.44 (s, 1H), 6.99 (s, 1H), 6.42 (brs, 1H),
4.32 (brs 2H), 3.99 (s, 6H), 3.41–3.43 (m, 2H), 2.70 (s, 3H); IR
(KBr) mmax/cm–1 3435 (N–H str.), 3142 (C–H), 1533 (C‚O),
1434 (SO2NH), 1330 (C–F), 1225 (C–O), 1168 (C–H), 765 (C–
N), 673 (C–Br); MS (APCI); m/z 552[M+H]+; HPLC; 98%
4.6.4. Synthesis of 2-Chloro-N-[2-(6, 7-dimethoxy-2-methyl-4-
oxo-4H-quinazolin-3-yl)-ethyl]-4-triﬂuoromethyl-
benzenesulphonamide (26)
White solid, Yield 85%, mp 184–186 C; 1H NMR (CDCl3,
300 MHz, d ppm): 7.77 (d, J = 7.2 Hz, 1H), 7.68 (d,
J = 7.2 Hz, 1H), 7.27–7.32 (s, 1H), 7.04 (s, 2H), 6.99 (brs,
1H), 4.28 (brs 2H), 3.86 (s, 6H), 3.04–3.09 (m, 2H), 2.50 (s,
3H); IR (KBr) mmax/cm–1 3400 (N–H str.), 3142 (C–H),
1540 (C‚O), 1418 (SO2NH), 1340 (C–F), 1203 (C–O), 1100
(C–H), 935 (C–N), 615 (C–Cl); MS (APCI); m/z
506[MH]+; HPLC; 99%.
4.6.5. Synthesis of N-[2-(6, 7-Dimethoxy-2-methyl-4-oxo-4H-
quinazolin-3-yl)-ethyl]-5-ﬂuoro-2-methyl-benzenesulphonamide
(27)
White solid, Yield 84%, mp 183–185 C; 1H NMR (CDCl3,
300 MHz, d ppm): 7.65–7.68 (m, 1H), 7.58 (s, 1H), 7.16–7.09
(m, 2H), 6.99 (s, 1H), 6.42 (brs, 1H), 4.29 (t, J = 6 Hz, 2H),
3.99 (s, 3H), 3.97 (s, 3H), 3.44–3.42 (m, 2H), 2.71 (s, 3H),
2.55 (s, 3H); IR (KBr) mmax/cm–1 3417 (N–H str), 3147 (C–
H), 1540 (C‚O), 1443 (SO2NH), 1355 (C–F), 1230 (C–O),Please cite this article in press as: Keche, A.P., Kamble, V.M. Synthesis and anti-inﬂa
one derivatives bearing urea, thiourea and sulphonamide functionalities. Arabian Jo1159 (C–H), 765 (C–N); MS (APCI); m/z 436.1[M+H]+;
HPLC; 98%.
4.6.6. Synthesis of N-[2-(6, 7-Dimethoxy-2-methyl-4-oxo-4H-
quinazolin-3-yl)-ethyl]-3, 4-dimethoxy-benzenesulphonamide
(28)
White solid, Yield 83%, mp 181–183 C; 1H NMR (DMSO-d6,
300 MHz, d ppm): 8.41 (d, J = 7.5 Hz, 1H), 8.13 (d,
J = 7.2 Hz, 1H), 7.91–7.97 (m, 1H), 7.43 (s, 1H), 7.06 (s,
1H), 6.19 (brs, 1H), 4.39 (t, J = 5.4 Hz, 2H), 3.88 (s, 6H),
3.86 (s, 6H), 3.47–3.43 (m, 2H), 2.62 (s, 3H); IR (KBr)
mmax/cm–1 3400 (N–H str.), 3142 (C–H), 1537 (C‚O), 1418
(SO2NH), 1236 (C–O), 1100 (C–H), 935 (C–N); MS (APCI);
m/z 464.3[M+H]+; HPLC; 96%.
4.6.7. Synthesis of N-[2-(6, 7-Dimethoxy-2-methyl-4-oxo-4H-
quinazolin-3-yl)-ethyl]-3-methyl-benzenesulphonamide (29)
White solid, Yield 85%, mp 184–186 C; 1H NMR (CDCl3,
300 MHz, d ppm): 7.89 (s, 1H), 7.55 (s, 2H), 7.35–7.39 (m,
3H), 7.04 (brs, 1H), 4.05 (t, J = 5.9 Hz, 2H), 3.88 (s, 3H),
3.85 (s, 3H), 3.08–3.10 (m, 2H), 2.72 (s, 3H), 2.34 (s, 3H); IR
(KBr) mmax/cm–1 3435 (N–H str.), 3148 (C–H), 1540
(C‚O), 1445 (SO2NH), 1230 (C–O), 1160 (C–H), 765 (C–
N); MS (APCI); m/z 418[M+H]+; HPLC; 98%.
4.7. Biological assay
4.7.1. Anti-inﬂammatory assay
Pro-inﬂammatory cytokine production by lip polysaccharide
(LPS) in THP-1 cells was measured according to the method
described by Hwang et al. (1993). During assay, THP-1 cells
were cultured in RPMI 1640 culture medium (Gibco BRL,
Paisley, UK) containing 100 U/mL penicillin and 100 mg/
mL streptomycin containing 10% foetal bovine serum (FBS,
JRH). Cells were differentiated with phorbol myristate acetate
(PMA, Sigma). Following cell plating, the test compounds in
0.5% DMSO were added to each well separately and the plate
was incubated for 30 min at 37 C. Finally, LPS (E. coli
0127:B8, Sigma Chemical Co., St. Louis, MO) was added,
at a ﬁnal concentration of 1 lg/mL in each well. Plates were
further incubated at 37 C for 24 h in 5% CO2. After incuba-
tion, supernatants were harvested, and assayed for TNF-a
and IL-6 by ELISA as described by the manufacturer (BD
Biosciences).
4.7.2. Antibacterial assay
Newly synthesized compounds were screened for their antibac-
terial activity against selected Gram-positive organisms viz. S.s
aureus (MTCC 96), B.s subtilis (MTCC 441) and Gram-nega-
tive organisms viz. E.s coli (MTCC 443), S. typhimurium
(MTCC 98) bacterial strains by the agar well diffusion method
with little modiﬁcation (Sridhar et al., 2004). Different concen-
trations (10–200 lg/ml) of test compounds were prepared in
DMSO. The bacterial suspension was spread over nutrient
agar plates and the well with of 6 mm diameter was punched
with sterile cork borer. The sample (50 lL) was added to the
well and the plates were incubated at 37 C for 24 h. Respec-
tive solvent control (DMSO) was kept and ciproﬂoxacin was
used as standard antibacterial agent. The lowest concentration
of compound which completely inhibits the bacterial growthmmatory and antimicrobial activities of some novel 2-methylquinazolin-4(3H)-
urnal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.10.025
10 A.P. Keche, V.M. Kamblewas taken as minimum inhibitory concentration (MIC). Mini-
mum inhibitory concentrations (MIC) were noted (Table 2).
4.7.3. Antifungal assay
Newly synthesized compounds were screened for their anti-
fungal activity against C. albicans (MTCC 227), Aspergillus
niger (MTCC 281), F.s solani (MTCC 350) and Aspergillus ﬂa-
vus (MTCC 277) by the agar well diffusion method with little
modiﬁcation (Sridhar et al., 2004). Normal saline was used to
make a suspension of spores of fungal strain. The fungal sus-
pension was spread over potato dextrose agar plates and the
wells of 6 mm diameter were punched with sterile cork borer.
The sample (50 lL) was added to the well and the plates were
incubated at 37 C for 2–3 days. Respective solvent control
(DMSO) was kept and miconazole was used as standard anti-
fungal agent. The lowest concentration of compound which
completely inhibits the fungal growth was taken as minimum
inhibitory concentration (MIC). Minimum inhibitory concen-
trations (MIC) were noted (Table 3).
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